Effect of Botulinum Toxin A Treatment on Eyelid Pressure in Eyes with Blepharospasm

References

• Ross AH, Elston JS, Marion MH, Malhotra R. Review and update of involuntary facial movement disorders presenting in the ophthalmological setting. Surv Opthalmol. 2011;56:54–67. doi:10.1016/j.survophthal.2010.03.008.
   PubMed Web of Science ®Google Scholar
• Valls-Sole J, Defazio G. Blepharospasm: update on epidemiology, clinical aspects, and pathophysiology. Front Neurol. 2016;7:45. doi:10.3389/fneur.2016.00045.
   PubMed Web of Science ®Google Scholar
• Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol. 2004;3:673–78. doi:10.1016/S1474-4422(04)00907-X.
   PubMed Web of Science ®Google Scholar
• Defazio G, Abbruzzese G, Aniello MS, Di Fede R, Esposito M, Fabbrini G, Girlanda P, Liguori R, Marinelli L, Martino D, et al. Eye symptoms in relatives of patients with primary adult-onset dystonia. Mov Disord. 2012;27:305–07. doi:10.1002/mds.24026.
   PubMed Web of Science ®Google Scholar
• Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10–24. doi:10.1113/jphysiol.1949.sp004364.
   PubMed Web of Science ®Google Scholar
• Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Opthalmol. 2007;52:13–31. doi:10.1016/j.survophthal.2006.10.003.
   PubMed Web of Science ®Google Scholar
• Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–50. doi:10.1001/archopht.1985.01050030043017.
   PubMedGoogle Scholar
• Tsoy EA, Buckley EG, Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol. 1985;99:176–79. doi:10.1016/0002-9394(85)90228-4.
   PubMed Web of Science ®Google Scholar
• Hellman A, Torres-Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord. 2015;8:82–91. doi:10.1177/1756285614557475.
   PubMed Web of Science ®Google Scholar
• Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober E-M, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003;87:54–56. doi:10.1136/bjo.87.1.54.
   PubMed Web of Science ®Google Scholar
• Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014;157:591–597.e2. doi:10.1016/j.ajo.2013.11.014.
   PubMed Web of Science ®Google Scholar
• Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13(Suppl 4):35–40. doi:10.1111/ene.2006.13.issue-s4.
   PubMed Web of Science ®Google Scholar
• Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5:249–66. doi:10.3390/toxins5020249.
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627–35. doi:10.1016/j.ophtha.2004.02.017.
   PubMed Web of Science ®Google Scholar
• Killer HE, Rust O, Muller O, Flammer J. Unilateral glaucomatous damage in a patient with hemifacial spasm. Ophthalmologica. 1999;213:273–75. doi:10.1159/000027436.
   PubMed Web of Science ®Google Scholar
• Lee MS, Harrison AR, Grossman DS, Sloan FA. Risk of glaucoma among patients with benign essential blepharospasm. Ophthal Plast Reconstr Surg. 2010;26:434–37. doi:10.1097/IOP.0b013e3181d3da43.
   PubMed Web of Science ®Google Scholar
• Nicoletti AG, Zacharias LC, Susanna R Jr, Matayoshi S. Patients with essential blepharospasm and glaucoma: case reports. Arq Bras Oftalmol. 2008;71:747–51. doi:10.1590/S0004-27492008000500028.
   PubMed Web of Science ®Google Scholar
• Sakai E, Shiraishi A, Yamaguchi M, Ohta K, Ohashi Y. Blepharo-tensiometer: new eyelid pressure measurement system using tactile pressure sensor. Eye Contact Lens. 2012;38:326–30. doi:10.1097/ICL.0b013e318268610a.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Shiraishi A, Sakane Y, Yamaguchi M, Ohta K, Ohashi Y. Involvement of eyelid pressure in lid-wiper epitheliopathy. Curr Eye Res. 2016;41(2):171–178. doi:10.3109/02713683.2015.1009636.
   Web of Science ®Google Scholar
• Yoshioka E, Yamaguchi M, Shiraishi A, Kono T, Ohta K, Ohashi Y. Influence of eyelid pressure on fluorescein staining of ocular surface in dry eyes. Am J Ophthalmol. 2015;160:685–692.e1. doi:10.1016/j.ajo.2015.06.028.
   PubMed Web of Science ®Google Scholar
• Georgescu D, Vagefi MR, McMullan TF, McCann JD, Anderson RL. Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol. 2008;145:541–47. doi:10.1016/j.ajo.2007.10.017.
   PubMed Web of Science ®Google Scholar
• Conte A, Fabbrini G, Belvisi D, Marsili L, Di Stasio F, Berardelli A. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm. Eur J Neurol. 2010;17:449–55. doi:10.1111/j.1468-1331.2009.02840.x.
   PubMed Web of Science ®Google Scholar
• Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology. 2002;58:1843–46. doi:10.1212/WNL.58.12.1843.
   PubMed Web of Science ®Google Scholar
• Boghen D, Tozlovanu V, Iancu A, Forget R. Botulinum toxin therapy for apraxia of lid opening. Ann N Y Acad Sci. 2002;956:482–83. doi:10.1111/nyas.2002.956.issue-1.
   PubMed Web of Science ®Google Scholar
• Elston JS, Marsden CD, Grandas F, Quinn NP. The significance of ophthalmological symptoms in idiopathic blepharospasm. Eye. 1988;2(Pt 4):435–39. doi:10.1038/eye.1988.79.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol. 1983;13:402–11. doi:10.1002/(ISSN)1531-8249.
   PubMed Web of Science ®Google Scholar
• Martino D, Defazio G, Alessio G, Abbruzzese G, Girlanda P, Tinazzi M, Fabbrini G, Marinelli L, Majorana G, Buccafusca M, et al. Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord. 2005;20:1564–70. doi:10.1002/(ISSN)1531-8257.
   PubMed Web of Science ®Google Scholar
• Rosenthal P, Baran I, Jacobs DS. Corneal pain without stain: is it real? Ocul Surf. 2009;7:28–40. doi:10.1016/S1542-0124(12)70290-2.
   PubMed Web of Science ®Google Scholar
• Rosenthal P, Borsook D. The corneal pain system. Part I: the missing piece of the dry eye puzzle. Ocul Surf. 2012;10:2–14. doi:10.1016/j.jtos.2012.01.002.
   PubMed Web of Science ®Google Scholar
• Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection. Eur J Ophthalmol. 2014;24:830–34. doi:10.5301/ejo.5000482.
   PubMed Web of Science ®Google Scholar
• Doane MG. Interactions of eyelids and tears in corneal wetting and the dynamics of the normal human eyeblink. Am J Ophthalmol. 1980;89:507–16. doi:10.1016/0002-9394(80)90058-6.
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group.The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505. doi:10.1016/S0002-9394(98)00272-4.
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group.Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–97. doi:10.1016/S0002-9394(98)00223-2.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79. doi:10.1001/archopht.120.10.1268.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13; discussion 829–730. doi:10.1001/archopht.120.6.701.
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–53. doi:10.1016/S0161-6420(01)00873-9.
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–40. doi:10.1016/S0002-9394(00)00538-9.
   PubMed Web of Science ®Google Scholar
• Coleman DJ, Trokel S. Direct-recorded intraocular pressure variations in a human subject. Arch Ophthalmol. 1969;82:637–40. doi:10.1001/archopht.1969.00990020633011.
   PubMed Web of Science ®Google Scholar